Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Anti-Cancer Drugs
|
November 26, 1999
Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
H Oettle, U Pelzer, K Hochmuth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2015
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
M Sinn, H Riess, B V Sinn, et al.
British Journal of Cancer
|
October 15, 2014
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
M Sinn, C Denkert, J K Striefler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
H Oettle, M Arning, U Pelzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2005
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
H Oettle, D Richards, R K Ramanathan, et al.
British Journal of Cancer
|
January 10, 2008
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
O Nehls, H Oettle, J T Hartmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study
M Sinn, B V Sinn, J K Striefler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H van de Velde, P Karasek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2020
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results
M Sinn, T Liersch, H Riess, et al.
BMC Cancer
|
October 24, 2019
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial
U A Wittel, D Lubgan, M Ghadimi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Anti-Cancer Drugs
|
November 26, 1999
Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
H Oettle, U Pelzer, K Hochmuth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2015
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
M Sinn, H Riess, B V Sinn, et al.
British Journal of Cancer
|
October 15, 2014
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
M Sinn, C Denkert, J K Striefler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
H Oettle, M Arning, U Pelzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2005
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
H Oettle, D Richards, R K Ramanathan, et al.
British Journal of Cancer
|
January 10, 2008
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
O Nehls, H Oettle, J T Hartmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study
M Sinn, B V Sinn, J K Striefler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H van de Velde, P Karasek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2020
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results
M Sinn, T Liersch, H Riess, et al.
BMC Cancer
|
October 24, 2019
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial
U A Wittel, D Lubgan, M Ghadimi, et al.
Page
of 6